IL6-induced metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of 3,3′-diindolylmethane in ovarian cancer cells

详细信息    查看全文

• 作者：Minghua Zou ; Xianquan Zhang ; Changhua Xu
• 关键词：3 ; 3′-Diindolylmethane ; ovarian cancer ; STAT3 ; metastasis ; IL6 ; MMP
• 刊名：Cellular Oncology
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：39
• 期：1
• 页码：47-57
• 全文大小：6,771 KB
• 参考文献：1.S. Vaughan, J.I. Coward, R.C. Bast Jr., A. Berchuck, J.S. Berek, J.D. Brenton, G. Coukos, C.C. Crum, R. Drapkin, D. Etemadmoghadam, M. Friedlander, H. Gabra, S.B. Kaye, C.J. Lord, E. Lengyel, D.A. Levine, I.A. McNeish, U. Menon, G.B. Mills, K.P. Nephew, A.M. Oza, A.K. Sood, E.A. Stronach, H. Walczak, D.D. Bowtell, F.R. Balkwill, Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 11, 719–725 (2011)PubMedCentral CrossRef PubMed
  2.Y. Li, K. Wang, Y.Z. Jiang, X.W. Chang, C.F. Dai, J. Zheng, 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD) inhibits human ovarian cancer cell proliferation. Cell Oncol 37, 429–437 (2014)CrossRef
  3.M. Momeni, T. Kalir, S. Farag, L. Chuang, D. Fishman, D.E. Burstein, Expression of H1. 5 and PLZF in granulosa cell tumors and normal ovarian tissues: a short report. Cell Oncol 37, 229–234 (2014)CrossRef
  4.J. Di, T. Duiveman-de Boer, P.L. Zusterzeel, C.G. Figdor, L.F.G. Massuger, R. Torensma, The stem cell markers Oct4A, Nanog and c-Myc are expressed in ascites cells and tumor tissue of ovarian cancer patients. Cell Oncol 36, 363–374 (2013)CrossRef
  5.R. Siegel, J. Ma, Z. Zou, A. Jemal, Cancer statistics, 2014. CA Cancer J Clin 64, 9–29 (2014)CrossRef PubMed
  6.R. Agarwal, S.B. Kaye, Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3, 502–516 (2003)CrossRef PubMed
  7.S. McNaughton, A, Marks G C, Development of a food composition database for the estimation of dietary intakes of glucosinolates, the biologically active constituents of cruciferous vegetables. Br J Nutr 90, 687–697 (2003)CrossRef PubMed
  8.K. Kandala, P, K Srivastava S, DIMming ovarian cancer growth. Curr Drug Targets 13(1869–1875) (2012)
  9.P.K. Kandala, S.K. Srivastava, Regulation of Janus-activated kinase-2 (JAK2) by diindolylmethane in ovarian cancer in vitro and in vivo. Drug Discov Ther 6, 94–101 (2012)PubMed
  10.L.M. Beaver, T.W. Yu, E.I. Sokolowski, D.E. Williams, R.H. Dashwood, E. Ho, 3, 3′-Diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells. Toxicol Appl Pharmacol 263, 345–351 (2012)PubMedCentral CrossRef PubMed
  11.S. Banerjee, Z. Wang, D. Kong, F.H. Sarkar, 3, 3′-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res 69, 5592–5600 (2009)PubMedCentral CrossRef PubMed
  12.Q.J. Wu, Y. Yang, E. Vogtmann, J. Wang, L.H. Han, H.L. Li, Y.B. Xiang, Cruciferous vegetables intake and the risk of colorectal cancer: a meta-analysis of observational studies. Ann Oncol 24, 1079–1087 (2013)PubMedCentral CrossRef PubMed
  13.B.B. Aggarwal, H. Ichikawa, Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle 4, 1201–1215 (2005)CrossRef PubMed
  14.D. Kong, Y. Li, Z. Wang, S. Banerjee, F.H. Sarkar, Inhibition of angiogenesis and invasion by 3, 3′-Diindolylmethane is mediated by the Nuclear Factor-κB downstream target genes MMP-9 and uPA that regulate bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 67, 3310–3319 (2007)CrossRef PubMed
  15.A. Aamir, B. Bernhard, L. Yiwei, K. Dejuan, B. Bin, S. Rainer, B. Subhash, H. Fazlul, Sarkar, Targeted regulation of PI3K/Akt/mTOR/NF-κB signaling by indole compounds and their derivatives: mechanistic details and biological implications for cancer therapy. Anticancer Agents Med Chem 13, 1002 (2013)CrossRef
  16.P.K. Kandala, S.E. Wright, S.K. Srivastava, Blocking epidermal growth factor receptor activation by 3, 3′-diindolylmethane suppresses ovarian tumor growth in vitro and in vivo. J Pharmacol Exp Ther 341, 24–32 (2012)PubMedCentral CrossRef PubMed
  17.A. Maccio, C. Madeddu, Inflammation and ovarian cancer. Cytokine 58, 133–147 (2012)CrossRef PubMed
  18.J. Coward, H. Kulbe, P. Chakravarty, D. Leader, V. Vassileva, D.A. Leinster, R. Thompson, T. Schioppa, J. Nemeth, J. Vermeulen, N. Singh, N. Avril, J. Cummings, E. Rexhepaj, K. Jirström, W.M. Gallagher, D.J. Brennan, I.A. McNeish, F.R. Balkwill, Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 17, 6083–6096 (2011)PubMedCentral CrossRef PubMed
  19.Y. Guo, F. Xu, T. Lu, Z. Duan, Z. Zhang, Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 38, 904–910 (2012)CrossRef PubMed
  20.G. Gastl, M. Plante, Bioactive interleukin-6 levels in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Methods Mol Med 39, 121–123 (2001)PubMed
  21.E.M. Dijkgraaf, M.J. Welters, J.W. Nortier, S.H. van der Burg, J.R. Kroep, Interleukin-6/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer. Curr Pharm Des 18, 3816–3827 (2012)CrossRef PubMed
  22.Y. Wang, L. Li, X. Guo, X. Jin, W. Sun, X. Zhang, R.C. Xu, Signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. Cytokine 59, 228–236 (2012)CrossRef PubMed
  23.N. Shah, K. Jin, L.A. Cruz, S. Park, H. Sadik, S. Cho, C.P. Goswami, H. Nakshatri, R. Gupta, H.Y. Chang, Z. Zhang, A. Cimino-Mathews, L. Cope, C. Umbricht, S. Sukumar, HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression. Cancer Res 73, 5449–5458 (2013)PubMedCentral CrossRef PubMed
  24.V.P.S. Garikapaty, B.T. Ashok, K. Tadi, A. Mittelman, R.K. Tiwari, Synthetic dimer of indole-3-carbinol: second generation diet derived anti-cancer agent in hormone sensitive prostate cancer. Prostate 66, 453–462 (2006)CrossRef PubMed
  25.K.M. Rahman, S. Ali, A. Aboukameel, S.H. Sarkar, Z. Wang, P.A. Philip, W.A. Sakr, A. Raz, Inactivation of NF- KB by 3, 3′-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells. Mol Cancer Ther 6, 2757–2765 (2007)CrossRef PubMed
  26.L. Xue, G.L. Firestone, L.F. Bjeldanes, DIM stimulates IFNgamma gene expression in human breast cancer cells via the specific activation of JNK and p38 pathways. Oncogene 24, 2343–2353 (2005)CrossRef PubMed
  27.M. Walter, S. Liang, S. Ghosh, P.J. Hornsby, R. Li, Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells. Oncogene 28, 2745–2755 (2009)PubMedCentral CrossRef PubMed
  28.D. Hanahan, R.A. Weinberg, The hallmarks of cancer. Cell 100, 57–70 (2000)CrossRef PubMed
  29.G.P. Gupta, J. Massagué, Cancer metastasis: building a framework. Cell 127, 679–695 (2006)CrossRef PubMed
  30.B. Tu, L. Du, Q.M. Fan, Z. Tang, T.T. Tang, STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma. Cancer Lett 325, 80–88 (2012)CrossRef PubMed
  31.S. Bellone, K. Watts, S. Cane, M. Palmieri, M.J. Cannon, A. Burnett, xAlexander BurnettSearch for articles by this author Roman JJ, Pecorelli S, Santin AD, High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and Affiliations Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA chemotherapy-resistant variant of endometrial cancer. Gynecol Oncol 98, 92–98 (2005)CrossRef PubMed
  32.N. Songur, B. Kuru, F. Kalkan, C. Ozdilekcan, H. Cakmak, N. Hizel, Serum interleukin-6 levels correlate with malnutrition and survival in patients with advanced non-small cell lung cancer. Tumori 90, 196–200 (2004)PubMed
  33.I. Garcia-Tunon, M. Ricote, A. Ruiz, B. Fraile, R. Paniagua, M. Royuela, IL-6, its receptors and its relationship with bcl-2 and bax proteins in infiltrating and in situ human breast carcinoma. Histopathology 47, 82–89 (2005)CrossRef PubMed
  34.R. Salgado, S. Junius, I. Benoy, P. Van Dam, P. Vermeulen, E. Van Marck, P. Huget, L. Dirk, Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 103, 642–646 (2003)CrossRef PubMed
  35.I. Zakrzewska, J. Poznanski, Changes of serum IL-6 and CRP after chemotherapy in patients with ovarian carcinoma. Pol Merkur Lekarski 11, 210–213 (2001)PubMed
  36.R.T. Penson, K. Kronish, Z. Duan, A.J. Feller, P. Stark, S.E. Cook, L.R. Duska, A.F. Fuller, A.K. Goodman, N. Nikrui, K.M. MacNeill, U.A. Matulonis, F.I. Preffer, M.V. Seiden, Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1. GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Can 10, 33–41 (2000)CrossRef
  37.D.G. Rosen, I. Mercado-Uribe, G. Yang, R.C. Bast Jr., H.M. Amin, R. Lai, J. Liu, The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer 107, 2730–2740 (2006)CrossRef PubMed
  38.N. de la Iglesia, S.V. Puram, A. Bonni, STAT3 regulation of glioblastoma pathogenesis. Curr Mol Med 9, 580–590 (2009)PubMedCentral CrossRef PubMed
  39.M. Musteanu, L. Blaas, M. Mair, M. Schlederer, M. Bilban, S. Tauber, H. Esterbauer, M. Mueller, E. Casanova, L. Kenner, V. Poli, R. Eferl, Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice. Gastroenterology 138, 1003–1011 (2010)CrossRef PubMed
  40.J.P. Couto, L. Daly, A. Almeida, J.A. Knauf, J.A. Fagin, M. Sobrinho-Simoes, J. Lima, V. Maximo, P. Soares, D. Lyden, J. Bromberg, STAT3 negatively regulates thyroid tumorigenesis. Proc Natl Acad Sci U S A 109, 2361–2370 (2012)CrossRef
  41.J.F. Torres-Roca, M. DeSilvio, L.B. Mora, L.Y. Khor, E. Hammond, N. Ahmad, R. Jove, J. Forman, R.J. Lee, H. Sandler, A. Pollack, Activated STAT3 as a correlate of distant metastasis in prostate cancer: a secondary analysis of Radiation Therapy Oncology Group 86–10. Urology 69, 505–509 (2007)CrossRef PubMed
  42.N. Yanaihara, M.S. Anglesio, K. Ochiai, Y. Hirata, M. Saito, C. Nagata, Y. Lida, S. Takakura, K. Yamada, T. Tanaka, A. Okamoto, Cytokine gene expression signature in ovarian clear cell carcinoma. Int J Oncol 41, 1094–1100 (2012)PubMed
  43.S. Chakraborti, M. Mandal, S. Das, A. Mandal, T. Chakraborti, Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 253, 269–285 (2003)CrossRef PubMed
  44.S.P. Gao, J.F. Bromberg, Touched and moved by STAT3. Sci. Signaling. 2006, pe30 (2006)
  
• 作者单位：Minghua Zou (1)
  Xianquan Zhang (1)
  Changhua Xu (1)
  
  1. Department of Oncology, The Second Affiliated Hospital, Chongqing Medical University, 74 Linjiang Road, Chongqing, 400010, China
  
• 刊物主题：Cancer Research; Biomedicine general; Pathology; Oncology;
• 出版者：Springer Netherlands
• ISSN：2211-3436

文摘

Purpose Ovarian cancer is a highly lethal gynecological malignancy for which the overall prognosis has remained poor over the past few decades. Interleukin (IL6) has been found to be a major contributor to the initiation and progression of ovarian cancer. This cytokine exerts its activity through activation of several signaling pathways, in particular the signal transducer and activator of transcription (STAT3) pathway. Here, we aimed at investigating the capacity of a natural dietary compound found in cruciferous vegetables, i.e., 3,3′-diindolylmethane (DIM), to target the metastatic phenotype of ovarian cancer cells through functional p-STAT3.